Joseph Holthoff

Dr. Joseph Holthoff

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
JHJoseph Holthoff
Joseph Holthoff
YHYanping Harville
Yanping Harville
CHChristian Herzog
Christian Herzog
LJLuis A. Juncos
Luis A. Juncos
NKNithin Karakala
Nithin Karakala
JAJohn M. Arthur
John M. Arthur
Background: Acute kidney injury (AKI) is a major burden among hospitalized and critical care patients. Among hospitalized patients that progress to severe AKI there is increased risk for morbidity, mortality, and the need for renal replacement therapy (RRT). As there are no specific treatments for AKI, the discovery of novel biomarkers that predict the progression of AKI may aid in timely implementation of supportive care to improve outcomes. Methods: We collected urine from 204 patients that developed Stage 1 AKI by AKIN criteria within 72 h following cardiothoracic surgery. Urine samples were collected at the time of the initial diagnosis of AKI and stored at −80° C. Among the 204 patients, 25 progressed to a composite primary outcome of Stage 3 AKI, requirement of RRT, or 30-day mortality. The remaining 179 patients did not progress beyond Stage 2 AKI and were considered controls. Urinary concentrations of SOD1 and SOD1 activity were measured following collection of all samples. Samples were thawed and urinary superoxide dismutase 1 (SOD1) concentrations were measured by sandwich ELISA and urinary SOD1 activity was measured through a commercially available colorimetric assay. Results: Urinary concentrations of SOD1 were significantly elevated (67.0 ± 10.1 VS 880.3 ± 228.8 ng/ml, p < 0.0001) in patients that progressed to severe AKI and were able to predict the progression to severe AKI (AUC – 0.85, p < 0.0001). Furthermore, total SOD activity also increased in the urine of patients that required RRT (77.6% VS 49.81% median inhibition, p < 0.01) and was able to predict the need for RRT (AUC: 0.83, p < 0.01). Conclusion: These findings show that urinary SOD1 concentrations and SOD activity are novel prognostic biomarkers for severe AKI following cardiothoracic surgery.

27 September 2024 in Genes
Verified
Journal Article
Open access
PDF file
VRVanya Rai
Vanya Rai
MSManisha Singh
Manisha Singh
JHJoseph Holthoff
Joseph Holthoff
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most prevalent heritable disorders, characterized by the progressive development of kidney cysts leading to renal failure. It is primarily caused by mutations in the PKD1 and PKD2 genes, which account for approximately 85% and 15% of cases, respectively. This case report describes a previously unreported mutation in the PKD1 gene, identified in a family involving an aunt and her niece with ADPKD. Case Presentation: The index case, a 56-year-old female with chronic kidney disease stage 3b secondary to ADPKD and hypertension, exhibited a strong family history of polycystic kidney disease (PKD). Initial genetic evaluations did not identify any recognized pathogenic mutations, leading to a more detailed investigation which revealed a novel mutation in the PKD1 gene. This mutation was also found in her niece, who presented with early-onset disease. Conclusions: The identification of a heterozygous six-nucleotide deletion, c.2084_2089del, resulting in the in-frame deletion of two amino acids, p.Pro695_Ala696del, in the PKD1 gene, has been linked with ADPKD in these patients. This report emphasizes the need for continuous updates to genetic data for a deeper understanding of the diagnosis and prognosis of ADPKD that could potentially aid in targeted therapy.

1 May 2025 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
JHJoseph Holthoff
Joseph Holthoff
NKNithin Karakala
Nithin Karakala
Alexei BasnakianAlexei Basnakian
Alexei Basnakian
RERicky D. Edmondson
Ricky D. Edmondson
TFTodd Wesley Fite
Todd Wesley Fite
JAJohn M. Arthur
John M. Arthur
The ability to predict progression to severe AKI remains an unmet challenge. Early prognostic biomarkers of AKI hold promise to improve patient outcomes by early implementation of clinical therapy, as well as unravel the pathophysiological mechanisms of AKI. Here, we present a novel urinary biomarker, IGFBP-1, that predicts the progression to severe AKI following cardiac surgery. In addition, we show that IGFBP-1 mice are protected against CIAKI, suggesting a mechanistic role for IGFBP-1 in AKI.

29 December 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
JHJoseph Holthoff
Joseph Holthoff
KCKiran Chandrashekar
Kiran Chandrashekar
LJLuis Juncos
Luis Juncos

1 January 2025 in Case Reports in Nephrology
Verified
Journal Article
Open access
FAFatima Ayub
Fatima Ayub
PEPRAVEEN ERRABELLI
PRAVEEN ERRABELLI
AAAbedalrahman Almashayekh
Abedalrahman Almashayekh
AAAhmed Abdallah
Ahmed Abdallah
RHRajibul Hasan
Rajibul Hasan
JHJoseph Holthoff
Joseph Holthoff
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used in patients with kidney disease and have been shown to increase serum magnesium levels. Case reports have described their role in correcting hypomagnesemia; however, there is limited evidence regarding their efficacy in patients with renal magnesium wasting. Furthermore, data regarding their role in acute treatment and sustained efficacy to treat hypomagnesemia are lacking. We present a multicenter retrospective, observational case series from two U.S. medical centers describing five patients with refractory hypomagnesemia who experienced significant improvement following initiation of SGLT2 inhibitors. Patients 1–4 showed marked renal magnesium wasting with severe symptomatic hypomagnesemia which responded robustly to SGLT2 inhibitor therapy. Even though Patient 5 did not have renal magnesium wasting, hypomagnesemia still improved with the addition of an SGLT2 inhibitor. Furthermore, the addition of an SGLT2 inhibitor acutely improved the hypomagnesemia of Patients 1 and 2 in an inpatient setting, and Patients 3–5 demonstrated sustained improvement of hypomagnesemia across extended outpatient follow‐up. The improvement of hypomagnesemia was irrespective of the diabetic status of the patient. All cases resulted in substantial reduction or cessation of magnesium (Mg) supplementation. These findings suggest a novel therapeutic application of SGLT2 inhibitors for managing intractable hypomagnesemia, both acutely and chronically, regardless of the diabetes being the primary culprit.

20 November 2025 in Kidney360
Verified
Journal Article
Closed access
FAFatima Ayub
Fatima Ayub
JHJoseph Holthoff
Joseph Holthoff